Literature DB >> 26083005

Comparison of safety and immunogenicity of 2 WHO prequalified rabies vaccines administered by one week, 4 site intra dermal regimen (4-4-4-0-0) in animal bite cases.

Ashwath Narayana1, Aravind Manoharan, Madhusudana Shampur Narayan, Sudarshan Mysore Kalappa, Gangaboraiah Biligumba, Ravish Haradanahalli, Ashwini Manoor Anand.   

Abstract

The currently advocated rabies post-exposure prophylaxis regimens are of one month duration with reduced patient compliance. WHO recommended research on shortened vaccination regimens which have a practical and economic advantage over the existing regimens. Hence, the present study was undertaken to assess the safety and immunogenicity of 2 WHO prequalified rabies vaccines administered by one week, 4 site intra dermal regimen (4-4-4-0-0) in animal bite cases. This study was a comparative, open label, phase III, randomized clinical trial conducted at Anti rabies clinic, KIMS Hospital, Bangalore, India. The study was registered in Clinical Trials Registry of India (CTRI) bearing the registration number CTRI/2012/12/003230. Ninety subjects with category II/III animal bites/exposures were enrolled. Equine rabies immunoglobulin was administered to all category III exposures. 0.1 mL of either purified chick embryo cell vaccine (Rabipur) or purified verocell rabies vaccine (Verorab) was administered intradermally into 4 sites on days 0, 3 and 7 to all the study subjects. Serum of subjects collected on day 0, 14, 90 and 365 were analyzed for rabies virus neutralizing antibody (RVNA) concentration. The incidence of ADR in Rabipur and Verorab group was 2.96% and 1.14% respectively. In Rabipur group, geometric mean concentration (95% confidence interval) of RVNA was 14.5 (13.50, 15.57), 11.78 (11.27, 12.31) and 5.95 (5.50, 6.44) IU/mL on days 14, 90 and 365 respectively; In Verorab group geometric mean concentration (95% confidence interval) of RVNA was 14.43 (13.41, 15.53), 11.93 (11.47, 12.40) and 5.67 (5.29, 6.08) IU/mL on days 14, 90 and 365 respectively. In conclusion, Rabipur and Verorab were found to be safe, immunogenic and comparable with each other, when administered using one week, 4 site intradermal regimen (4-4-4-0-0) in animal bite cases.

Entities:  

Keywords:  animal bite cases; immunogenicity; intradermal; one week 4 site regimen; rabipur; safety; verorab

Mesh:

Substances:

Year:  2015        PMID: 26083005      PMCID: PMC4517453          DOI: 10.1080/21645515.2015.1048938

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  17 in total

1.  Evaluation of two intradermal vaccination regimens using purified chick embryo cell vaccine for post-exposure prophylaxis of rabies.

Authors:  S N Madhusudana; N P Anand; R Shamsundar
Journal:  Natl Med J India       Date:  2001 May-Jun       Impact factor: 0.537

2.  A comparative study on the safety and immunogenicity of Purified duck embryo vaccine [corrected] (PDEV, Vaxirab) with purified chick embryo cell vaccine (PCEC, Rabipur) and purifed vero cell rabies vaccine (PVRV, Verorab).

Authors:  Doddabele Hanumantaiah Ashwathnarayana; Shampur Narayana Madhusudana; Gadey Sampath; Durga Madhab Sathpathy; Ranjit Mankeshwar; Haradana Halli Shankariah Ravish; Padinjaremattathil Thankappan Ullas; Tapas Ranjan Behra; Mysore Kalappa Sudarshan; Manjula Shamanna
Journal:  Vaccine       Date:  2009-10-08       Impact factor: 3.641

3.  Postexposure rabies prophylaxis completed in 1 week: preliminary study.

Authors:  Prapimporn Shantavasinkul; Thanphet Tantawichien; Henry Wilde; Artikaya Sawangvaree; Apinya Kumchat; Natthasri Ruksaket; Vitool Lohsoonthorn; Pakamatz Khawplod; Terapong Tantawichien
Journal:  Clin Infect Dis       Date:  2010-01-01       Impact factor: 9.079

4.  A simplified and economical intradermal regimen of purified chick embryo cell rabies vaccine for postexposure prophylaxis.

Authors:  P Suntharasamai; P Chaiprasithikul; C Wasi; W Supanaranond; P Auewarakul; P Chanthavanich; A Supapochana; S Areeraksa; S Chittamas; S Jittapalapongsa
Journal:  Vaccine       Date:  1994-05       Impact factor: 3.641

5.  Safety and Immunogenicity of purified chick embryo cell rabies vaccine (VaxiRab N) administered intradermally as post exposure prophylaxis.

Authors:  Hardanahalli S Ravish; Veena Vijayashankar; Shampur N Madhusudana; Mysore K Sudarshan; Doddabele Ha Narayana; Gangaboraiah Andanaiah; Belludi Y Ashwin; Annadani R Rachana; Manjula Shamanna
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

6.  Immunogenicity and safety study of Indirab: a Vero cell based chromatographically purified human rabies vaccine.

Authors:  Gadey Sampath; Shampur Narayan Madhusudana; Mysore Kalappa Sudarshan; Doddabele Hanumanthaiah Ashwathnarayana; Bangalore Jayakrishna Mahendra; Thankappan P Ullas; Krishna Mohan; Santhosh Kumar Madhusudhan; Haradanahalli Shankariah Ravish
Journal:  Vaccine       Date:  2010-04-18       Impact factor: 3.641

7.  Evaluation of a one week intradermal regimen for rabies post-exposure prophylaxis: results of a randomized, open label, active-controlled trial in healthy adult volunteers in India.

Authors:  Mysore Kalappa Sudarshan; Doddabele Hanumanthaiah Ashwath Narayana; Shampur Narayan Madhusudana; Ramesh Holla; Belludi Yajaman Ashwin; Bilagumba Gangaboraiah; Haradanahalli S Ravish
Journal:  Hum Vaccin Immunother       Date:  2012-08-01       Impact factor: 3.452

8.  Economical multiple-site intradermal immunisation with human diploid-cell-strain vaccine is effective for post-exposure rabies prophylaxis.

Authors:  M J Warrell; K G Nicholson; D A Warrell; P Suntharasamai; P Chanthavanich; C Viravan; A Sinhaseni; M K Chiewbambroongkiat; X Pouradier-Duteil; C Xueref
Journal:  Lancet       Date:  1985-05-11       Impact factor: 79.321

9.  WHO Expert Consultation on Rabies. Second report.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  2013

10.  Evaluation of cost-effective strategies for rabies post-exposure vaccination in low-income countries.

Authors:  Katie Hampson; Sarah Cleaveland; Deborah Briggs
Journal:  PLoS Negl Trop Dis       Date:  2011-03-08
View more
  4 in total

1.  Safety and Immunogenicity of a novel three-dose recombinant nanoparticle rabies G protein vaccine administered as simulated post exposure immunization: A randomized, comparator controlled, multicenter, phase III clinical study.

Authors:  Ravish H S; Akash Khobragade; Durga Satapathy; Monica Gupta; Surendra Kumar; Vinay Bhomia; Ramasubramanian V; Maharshi Desai; Ashok Dilipkumar Agrawal
Journal:  Hum Vaccin Immunother       Date:  2021-09-09       Impact factor: 4.526

2.  Shortening intradermal rabies post-exposure prophylaxis regimens to 1 week: Results from a phase III clinical trial in children, adolescents and adults.

Authors:  Phirangkul Kerdpanich; Pornthep Chanthavanich; Mari Rose De Los Reyes; Jodor Lim; Delia Yu; Ma Cecilia Ama; Zenaida Mojares; Daniela Casula; Ashwani Kumar Arora; Michele Pellegrini
Journal:  PLoS Negl Trop Dis       Date:  2018-06-06

3.  Modelling to inform prophylaxis regimens to prevent human rabies.

Authors:  Katie Hampson; Bernadette Abela-Ridder; Omesh Bharti; Lea Knopf; Monique Léchenne; Rolande Mindekem; Arnaud Tarantola; Jakob Zinsstag; Caroline Trotter
Journal:  Vaccine       Date:  2018-12-07       Impact factor: 4.169

Review 4.  Heterogeneity of Rabies Vaccination Recommendations across Asia.

Authors:  Philippe Buchy; Scott Preiss; Ved Singh; Piyali Mukherjee
Journal:  Trop Med Infect Dis       Date:  2017-07-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.